Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | TYR | P14679 | 3/20 | 0.52 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23258806 | 0.84 | TRPA1 (0.52) | TRPA1PTGS1CACNA1CALDH1A1ALOX12 | |
| SCHEMBL21408578 | 0.82 | TRPA1 (0.39) | TRPA1PTGS1CACNA1CALDH1A1ALOX12 | |
| SCHEMBL1438719 | 0.82 | GAA (0.57) | TRPA1PTGS1CACNA1CALDH1A1ALOX12 | |
| SCHEMBL1758484 | 0.79 | KDM1A (0.38) | TRPA1PTGS1CACNA1CHIF1AGAA | |
| SCHEMBL339292 | 0.78 | TRPA1 (0.67) | TRPA1PTGS1CACNA1CALDH1A1ALOX12 | |
| SCHEMBL6895537 | 0.78 | LMNA (0.44) | TRPA1PTGS1CACNA1CALDH1A1ALOX12 | |
| SCHEMBL29362968 | 0.78 | TRPA1 (0.67) | TRPA1PTGS1CACNA1CALDH1A1ALOX12 | |
| SCHEMBL172232 | 0.78 | TRPA1 (0.67) | TRPA1PTGS1CACNA1CALDH1A1ALOX12 | |
| SCHEMBL29661836 | 0.78 | LMNA (0.44) | TRPA1PTGS1CACNA1CALDH1A1ALOX12 | |
| SCHEMBL11511505 | 0.77 | ALOX15 (0.42) | TRPA1PTGS1CACNA1CALDH1A1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122037020-A | Supported catalyst, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122037020-A | Supported catalyst, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4661966-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | Type6 Therapeutics, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-116217599-B | Boron nitride compound, application and organic electroluminescent device comprising boron nitride compound | 浙江华显光电科技有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20250066309-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250025462-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2025-01-23 | — | — | US | disclosed |
| US-20240285620-A1 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | Afferent Pharmaceuticals, Inc. (US) | 2024-08-29 | — | — | US | disclosed |
| WO-2024167848-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | TYPE6 THERAPEUTICS, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240158356-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2024-05-16 | — | — | US | disclosed |
| CN-114621269-B | Condensed ring aromatic compound and application thereof in electroluminescent device | 清华大学 | 2024-04-09 | — | — | CN | disclosed |
| WO-2007025925-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049609-A1 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049609-A1 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049609-A1 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1725540-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| CN-1816536-A | Cannabinoid receptor modulators | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-08-09 | — | — | CN | disclosed |
| EP-1637527-A1 | CANNABINOID RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005095359-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| US-20050209260-A1 | Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine | ROCHE PALO ALTO LLC | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | TRPA1 4672/4885PTGS1 2743/4885CACNA1C 4598/4885 |
| US-20250066309-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | TRPA1 183/4885PTGS1 1409/4885CACNA1C 903/4885 |
| US-20050209260-A1 | Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine | P2RX3, P2RX2, P2RX1 | TRPA1 104/4885PTGS1 826/4885CACNA1C 964/4885 |
| US-20250025462-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | TRPA1 234/4885PTGS1 840/4885CACNA1C 1308/4885 |
| US-20240158356-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | TRPA1 183/4885PTGS1 1409/4885CACNA1C 903/4885 |
| US-20070049609-A1 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | P2RX3, P2RX2, P2RX1 | TRPA1 234/4885PTGS1 840/4885CACNA1C 1308/4885 |
| US-20240285620-A1 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | P2RX3, P2RX2, P2RX5 | TRPA1 24/4885PTGS1 375/4885CACNA1C 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.